OrbiMed Advisors LLC's Form 4 filing
Turnstone Biologics Corp. (TSBX) · filed Jul 24, 2023
- Accession no.
- 0000947871-23-000777
- Filed
- Jul 24, 2023, 4:38 PM ET
- Trade date
- Jul 20, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 4 derivative transactions. Open-market purchases total $5.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director, 10% Owner |
| OrbiMed Capital GP VI LLCCIK 0001682115 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 20, 2023 | Common Stock | CConversionAcquired | +2,682,599 | –F1 | – | 2,682,599 | Indirect | Duplicate filing |
| Jul 20, 2023 | Common Stock | PPurchaseAcquired | +416,666 | $12.00 | +$4,999,992 | 3,099,265 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 20, 2023 | Common Stock | CConversionDisposed | −937,372 | –F1 | – | 0 | Indirect | Duplicate filing |
| Jul 20, 2023 | Common Stock | CConversionDisposed | −1,249,829 | –F1 | – | 0 | Indirect | Duplicate filing |
| Jul 20, 2023 | Common Stock | CConversionDisposed | −266,240 | –F1 | – | 0 | Indirect | Duplicate filing |
| Jul 20, 2023 | Common Stock | CConversionDisposed | −229,158 | –F1 | – | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
Referenced by the price of 1 transaction in Table I and 4 transactions in Table II.